These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24867973)

  • 21. Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
    Miller MD; Haddad M; Su C; Gibbs C; McColl DJ; Guyer B
    Antivir Ther; 2012; 17(6):993-9. PubMed ID: 22837442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
    Svarovskaia ES; Feng JY; Margot NA; Myrick F; Goodman D; Ly JK; White KL; Kutty N; Wang R; Borroto-Esoda K; Miller MD
    J Acquir Immune Defic Syndr; 2008 Aug; 48(4):428-36. PubMed ID: 18614922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
    HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.
    Naeger LK; Margot NA; Miller MD
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2179-84. PubMed ID: 12069972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD81 association with SAMHD1 enhances HIV-1 reverse transcription by increasing dNTP levels.
    Rocha-Perugini V; Suárez H; Álvarez S; López-Martín S; Lenzi GM; Vences-Catalán F; Levy S; Kim B; Muñoz-Fernández MA; Sánchez-Madrid F; Yáñez-Mó M
    Nat Microbiol; 2017 Nov; 2(11):1513-1522. PubMed ID: 28871089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.
    Melikian GL; Rhee SY; Taylor J; Fessel WJ; Kaufman D; Towner W; Troia-Cancio PV; Zolopa A; Robbins GK; Kagan R; Israelski D; Shafer RW
    Antimicrob Agents Chemother; 2012 May; 56(5):2305-13. PubMed ID: 22330916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.
    Hukezalie KR; Thumati NR; Côté HC; Wong JM
    PLoS One; 2012; 7(11):e47505. PubMed ID: 23166583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients.
    Betancor G; Nevot M; Mendieta J; Gómez-Puertas P; Martínez MA; Menéndez-Arias L
    Antiviral Res; 2014 Jun; 106():42-52. PubMed ID: 24667336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
    Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
    Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase.
    Ray AS
    AIDS Rev; 2005; 7(2):113-25. PubMed ID: 16092505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.
    Painter GR; Almond MR; Mao S; Liotta DC
    Curr Top Med Chem; 2004; 4(10):1035-44. PubMed ID: 15193137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection.
    von Kleist M; Metzner P; Marquet R; Schütte C
    PLoS Comput Biol; 2012 Jan; 8(1):e1002359. PubMed ID: 22275860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.
    Whitcomb JM; Parkin NT; Chappey C; Hellmann NS; Petropoulos CJ
    J Infect Dis; 2003 Oct; 188(7):992-1000. PubMed ID: 14513419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations.
    Uckun FM; Pendergrass S; Venkatachalam TK; Qazi S; Richman D
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3613-6. PubMed ID: 12384373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies of molecular mechanism of tenofovir against 3TC- and AZT-resistance mutant HIV-1 reverse transcriptase.
    Chong Y; Akula N; Chu CK
    Bioorg Med Chem Lett; 2003 Nov; 13(22):4019-22. PubMed ID: 14592498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.
    Duan C; Poticha D; Stoeckli TC; Petropoulos CJ; Whitcomb JM; McHenry CS; Kuritzkes DR
    J Infect Dis; 2001 Nov; 184(10):1336-40. PubMed ID: 11679926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
    Miller MD; Margot NA; Lamy PD; Fuller MD; Anton KE; Mulato AS; Cherrington JM
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):450-8. PubMed ID: 11511821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1.
    Heredia A; Davis CE; Reitz MS; Le NM; Wainberg MA; Foulke JS; Wang LX; Redfield RR
    J Infect Dis; 2013 Dec; 208(12):2085-94. PubMed ID: 23922365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
    Nitanda T; Wang X; Somekawa K; Yuasa S; Baba M
    Antivir Chem Chemother; 2001 May; 12(3):161-7. PubMed ID: 12959324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.